Despite the recognized potential of URAT1 as a therapeutic target for HUA and gout [21], significant challenges remain in its clinical development [22], and there is a notable gap in the comprehensive analysis of the patent landscape and the potential drug value of URAT1 inhibitors [2,10,23]. Here, SLC22A12 is linked to gout.